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e.saarsurgery is lacking. Recommendations and practices vary by country and unit. Several reports have
expressed concerns on gastroesophageal reflux disease (GERD) and its consequences after sleeve
gastrectomy (SG) and the risk of leaving a premalignant lesion in the excluded stomach after Roux-
en-Y gastric bypass (RYGB).
Objectives: We explored the number and types of clinically significant findings in preoperative EGDs
and how they associate with preexisting GERD-symptoms (SG) and premalignant lesions (RYGB). We
also studied how many reoperations were performed due to postoperative GERD in SG-patients.
Setting: University hospital.
Methods: We investigated preoperative EGD-findings and gastrointestinal symptoms before bariatric
surgery in all patients with a primary bariatric operation in our unit between December 2007 and May
2016.
Results: We performed 1474 operations: 1047 (71.0%) RYGB, 407 (27.6%) SG, and 20 (1.4%) others.
One thousand two hundred seventy-five (86.5%) preoperative EGD reports were analyzed: 647 (50.7%)
EGDs were completely normal. Altogether, 294 patients (23.0% of total) had a clinically significant finding
that was relevant for SG (hiatal hernia, esophagitis, Barrett’s esophagus, esophageal dysplasia), 144
(49.0%) of whom reported gastrointestinal symptoms. Twenty patients (1.6%) had a significant finding
relevant for RYGB (peptic ulcer, atrophic gastritis, gastrointestinal stromal tumor), and 6 (30%) reported
gastrointestinal symptoms. Thirteen (3.2%) SGs were converted into RYGB due to GERD.
Conclusions: Preoperative EGD is indicated before SG but not before RYGB for asymptomatic
patients without a risk for gastric pathology. (Surg Obes Relat Dis 2018;]:00–00.) r 2018 American
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inen@hus.fiObesity is a vastly growing worldwide epidemic, and its
severe (body mass index [BMI] 435) and morbid
(BMI 440) forms especially have been increasing in the
recent years [1,2]. Surgical treatment has been shown to be
the most effective treatment not only for severe obesity but
also for its complications, such as type 2 diabetes (T2D)—
the reason why it is often called metabolic surgery [3]. In
2014, 579,517 bariatric operations were performed in the








































































































T. Saarinen et al. / Surgery for Obesity and Related Diseases ] (2018) 00–002procedure was sleeve gastrectomy (SG) followed by
Roux-en-Y gastric bypass (RYGB; 45.9% and 39.6% of
operations, respectively) [4]. In general, SG and RYGB
have proven to be effective in terms of weight reduction [5].
However, differences exist regarding effect on co-morbid-
ities, especially T2D [6].
Each bariatric procedure has to be tailored individually
according the patient’s overall health status and preexisting
diseases. The findings from preoperative evaluation need to
be taken into consideration when planning the surgery.
Preoperative esophagogastroduodenoscopy (EGD) is the
best tool for assessing the upper gastrointestinal (GI) status
[7]. EGD assessment before RYGB stems from a fear of
leaving a potential malignancy or a severe lesion in need of
surveillance in the excluded portion of the GI tract. On the
other hand, several reports have shown difficult gastro-
esophageal reflux disease (GERD) after SG, both de novo
and worsening of preexisting disease, which in either case
may lead to Barrett’s esophagus or need for reoperation
[8,9]. Thus, in theory, both RYGB and SG have reasons for
which a routine preoperative EGD may be warranted.
Guidelines as well as clinical practices regarding routine
preoperative EGD vary markedly. The European Associa-
tion for Endoscopic Surgery recommends routine EGD or
radiologic evaluation with a barium meal before bariatric
surgery, whereas the Society of American Gastrointestinal
and Endoscopic Surgeons recommends EGD when suspi-
cion of gastric pathology exists [10,11]. A recent survey of
British Obesity & Metabolic Surgery Society Members
showed that in the United Kingdom, 10% of bariatric units
consider preoperative EGD completely unnecessary,
whereas 31% include EGD in their routine preoperative
assessment [12].
In the present study, our aim was to assess the need for
EGD before RYGB and SG based on a large retrospective
cohort of bariatric operations in the Helsinki University
Hospital area. We set out to explore how many significant
findings were present in all preoperative EGD reports of our
unit between December 2007 and May 2016, with a special
emphasis on preoperative EGD findings and self-reported
preoperative symptoms related to GERD and findings that
require endoscopic follow-up especially due to potentially
premalignant conditions. We also focused on studying how
many reoperations were performed due to postoperative












We investigated the number and severity of macroscopic
and microscopic findings in preoperative EGD reports as
well as self-reported GI symptoms before bariatric surgery
from medical records of all patients who underwent a
primary bariatric operation between December 2007 andMay 2016 (n ¼ 1474) in Helsinki University Hospital.
Reoperation data after SG were collected from the same
period. We also obtained demographic data, including age,
BMI, and obesity-related co-morbidities, including T2D,
hypertension, dyslipidemia, sleep apnea, arthrosis, and
psychiatric disorders from our institutions’ bariatric registry
(BCB quality registry). EGD findings that needed to be
taken into consideration in preoperative planning were
classified as clinically significant. All findings that are
related to GERD were considered significant regarding
SG. These include esophagitis, Barrett’s esophagus, esoph-
ageal dysplasia, and hiatal hernia. All findings that require
either endoscopic follow-up or surgical resection were
considered significant regarding RYGB. These included
atrophic gastritis requiring endoscopic follow-up (atrophic
pangastritis and atrophic gastritis in the body of the stomach
with age o40 yr), peptic ulcers, and gastric neoplasms. The
surgical ethics committee of our institution approved the
study.Statistical analyses
We used parametric tests with this large data set to
analyze the statistical significance of the EGD findings.
Comparisons of means between groups of significant versus
normal/nonsignificant EGD findings as well as the avail-
ability of EGD report versus the whole sample were
analyzed with independent samples t tests. Dependence of
categorical variables with significant EGD findings and
availability of EGD report were analyzed with χ2 tests. We
used binary logistic regression models to determine whether
significant EGD findings were associated with any of the
co-morbidities, psychiatric diseases, age, sex, or BMI.
P o .05 was considered statistically significant. Values
are given as mean/median (standard deviation). Statistical
analysis was done using IBM SPSS Statistics 22 software
(Armonk, NY).Results
During December 2007 and May 2016, we performed
1474 primary bariatric operations: 1047 (71.0%) RYGB,
407 (27.6%) SG, and 20 (1.4%) others including mini-
gastric bypass, duodenal switch, and gastric balloon. One
thousand two hundred seventy-five (86.5%) preoperative
EGDs were performed with an available report. For 36
patients (2.4%), the EGD was performed outside our district
and the full EGD report was not available, and 163 (11.1%)
patients were operated without a preoperative EGD. This
was due to our unit’s guideline of 2013 to 2016, in which
patients aged o60 years without gastrointestinal symptoms
or risk factors for neoplasms would not need a preoperative
EGD. Demographic characteristics and co-morbidities of
the patients are given in Table 1. Age and BMI were both































































































Patient demographic characteristics and co-morbidities
Panel A Panel B















Total 1474 1275 (86.5%) 319 (25.0%) 956 (75.0%)
Women 1075 (72.9%) 926 (72.6%) .51* 244 (76.5%) 682 (71.3%) .074*
Age, yr (SD) 48.1 (9.2) 48.5 (9.1) o.001† 48.4 (8.7) 48.5 (9.2) .90†
BMI, kg/m2 (SD) 45.8 (6.9) 46.1 (7.0) o.001† 45.6 (7.1) 46.2 (7.0) .24†
No co-morbidities 317 (21.5%) 220 (17.3%) o.001* 60 (18.8%) 160 (16.7%) .40*
Type 2 diabetes 572 (38.8%) 528 (41.4%) o.001* 121 (37.9%) 407 (42.6%) .15*
Hypertension 708 (48.0%) 682 (53.5%) o.001* 148 (46.4%) 534 (55.9%) .003*
Dyslipidemia 360 (24.4%) 347 (27.2%) o.001* 83 (26.0%) 264 (27.6%) .58*
Arthrosis 648 (44.0%) 616 (48.3%) o.001* 150 (47.0%) 466 (48.7%) .59*
Asthma 193 (13.1%) 185 (14.5%) o.001* 48 (15.0%) 137 (14.3%) .75*
Psychiatric disease 315 (21.4%) 300 (23.5%) o.001* 77 (23.3%) 223 (24.1%) .77*
EGD ¼ esophagogastroduodenoscopy; SD ¼ standard deviation; BMI ¼ body mass index.
Panel A tests the patient characteristics between all patients and those with an available esophagogastroduodenoscopy (EGD). Panel B tests the patient
characteristics between those with or without a significant EGD finding. The significant EGD findings include esophagitis, Barrett’s esophagus, esophageal
dysplasia, hiatal hernia, atrophic gastritis, gastrointestinal stromal tumor, and peptic ulcer. Statistically significant P values are given in bold.
*P value, χ2.
†P value, independent samples t test.
Gastroscopy Before Bariatric Surgery / Surgery for Obesity and Related Diseases ] (2018) 00–00 3preoperative EGD report was available than in the whole
cohort. The proportion of all co-morbidities was signifi-
cantly higher in patients with a preoperative EGD.
Next, we calculated the number of normal and abnormal
EGDs. Out of the 1275 preoperative EGDs performed, 647
(50.7%) EGDs were completely normal (Table 2). An
abnormal finding was present in 628 (49.3%) patients,
and in 319 (24.6% of total) it was clinically significant.
No malignancies were found in preoperative EGDs. A great
majority (92%) of the clinically significant findings (294
patients, 23.0% of total) were relevant if the chosen
operation would be SG (hiatal hernia, esophagitis, Barrett’s
esophagus, esophageal dysplasia; Table 2). Approximately
half of these patients (144 patients, 49.0%) reported GITable 2
Clinically significant findings in preoperative esophagogastroduodenoscopies (EGD
nausea, and bloating) before bariatric surgery
n (%) G
N
All performed EGDs 1275
Significant finding in EGD 314 (24.6)
Findings significant for SG 294 (23.0) 10
Hiatal hernia 197(15.5) 66
Esophagitis 88 (6.9) 34
Barrett’s esophagus 47 (3.7) 19
Esophagusdysplasia 3 (.2) 2
Findings significant for RYGB 20 (1.6) 14
Peptic ulcer 12(.9) 8
Atrophic gastritis 7 (.5) 6
GIST 1 (.1) 0
SG ¼ Sleeve gastrectomy; RYGB ¼ Roux-en-Y gastric bypass; GIST ¼ gastsymptoms including reflux, regurgitation, dyspepsia, nau-
sea, and bloating before bariatric surgery, whereas 105
patients (35.7%) did not have any symptoms. For the rest
(45 patients), the medical records did not reveal whether
they had reflux symptoms before bariatric surgery. Only a
small proportion of patients with preoperative EGD (20
patients, 1.6%) had significant findings that would have
been relevant if the chosen operation is RYGB (peptic
ulcer, atrophic gastritis, GI stromal tumor). Six (30%)
reported GI symptoms before bariatric surgery (Table 2).
All patients with a peptic ulcer were taking nonsteroidal
anti-inflammatory drugs (NSAIDs). All patients except 1
with an atrophic gastritis requiring endoscopic follow-up


















) and gastrointestinal symptoms (including reflux, regurgitation, dyspepsia,
astrointestinal symptoms before surgery
o Yes Not reported
5 (35.7) 144 (49.0) 45 (15.3)
(33.5) 100 (50.8) 31 (15.7)
(38.6) 42 (47.7) 12 (13.6)
(40.4) 22 (46.8) 6 (12.8)
(66.7) 1 (33.3) 0
(70) 6 (30) 0
(66.7) 4 (33.3) 0





























































































T. Saarinen et al. / Surgery for Obesity and Related Diseases ] (2018) 00–004positive, or smokers). H. pylori staining was performed for
all EGD samples, and positive samples were found in 108
patients (8.5% of EGD reports).
Next, we assessed whether any of the clinical character-
istics or metabolic co-morbidities were associated with the
significant EGD findings. We found that the only statisti-
cally significant association was with hypertension and
normal/nonsignificant EGD findings (Table 1). Lack of
hypertension was also found to predict any significant EGD
finding (P ¼ .007) in binary logistic regression models.
Other variables (presence or absence of diabetes, dyslipi-
demia, sleep apnea, asthma, psychiatric disease, age, sex, or
BMI) were not statistically significantly associated with
clinically significant or nonsignificant EGD findings.
During the study period, 53 patients underwent SG
despite a clinically significant preoperative EGD finding
regarding SG. None required reoperation before May 2016
(median follow-up 4.18 yr, standard deviation 2.8). Ten
patients (18.9%, 5 with hiatal hernia, 3 with esophagitis,
and 2 with Barrett’s esophagus) have had several additional
visits due to reflux symptoms during the follow-up.
During our study period, 26 (6.4%) patients underwent a
reoperation after SG. Four were originally planned for a
2-stage procedure due to high preoperative BMI, with SG
later followed by single-anastomosis duodenoileal bypass.
Thirteen (3.2%) patients were converted to RYGB after SG
due to difficult reflux symptoms. None had a clinically
significant EGD finding preoperatively. Of these 13
patients, 10 reported no reflux symptoms after the con-
version to RYGB, and 3 continued to experience nausea
and epigastric pain after the conversion to RYGB. Eight
other patients were converted from SG to RYGB due to
insufficient weight loss without reflux symptoms. One
patient was converted to RYGB because of sleeve stenosis




















Our study shows a fairly high number (23.0%) of EGD
findings that have to be taken into consideration when
planning a SG. Moreover, nearly half the patients with a
significant EGD finding were asymptomatic. On the other
hand, EGD findings regarded as a contraindication for a
RYGB were quite rare (1.6%), and all but 1 patient were
either symptomatic or their risk for peptic ulcer or gastric
malignancy could be identified by age, smoking, H. pylori
infection, or NSAID usage. This implies that EGD seems to
be needed before SG but not before RYGB in asympto-
matic, low-risk patients.
The main indication for a preoperative EGD before SG is
the theory that SG accelerates the natural course of a
preexisting GERD on esophageal mucosa, which may
eventually lead to intolerable reflux symptoms, Barrett’s
esophagus, or even cancer in the long term. Several reports
have stated an increased risk of Barrett’s esophagus andincreased GERD after SG [13,14]. To our knowledge 3
cases of esophageal adenocarcinoma have been reported
after SG [15]. According to the International Sleeve
Gastrectomy Expert Panel Consensus Statement severe
esophagitis and Barrett’s esophagus are contraindications
for SG. The panel also stated that aggressive identification
of hiatal hernia is appropriate and should be repaired when
present [16]. Hiatal hernia has also been considered a
relative contraindication for SG [9]. Esophagitis, Barrett’s
esophagus, and hiatal hernia are very often asymptomatic—
in 40.3% of the patients in a previous study [17] and in
49.0% of patients in the present one. When we started doing
SG in 2007, there was no published data or personal
experience of GERD after SG. Therefore, we have pre-
viously performed SG for 53 patients with an EGD finding
that can now be considered a relative contraindication.
During the follow-up these patients have not undergone a
reoperation, but many have experienced more reflux symp-
toms after SG. Because there has been increasing evidence
of GERD after SG in the literature as well as in our own
experience, we currently avoid SG in patients with endo-
scopic sign of GERD when RYGB is feasible.
Reflux has been shown as the most common indication
for reoperation after SG, and it is often associated with
hiatal hernia [18]. A previous study from a high-volume
bariatric center reported 1.2% conversions from SG to
RYGB, and 62.5% were due to postoperative GERD with
or without insufficient weight loss [18]. During the follow-
up, we performed 13 (3.2%) reoperations after SG due to
difficult postoperative reflux, with 76.9% total recovery
from any reflux-related symptoms. A previous report
showed a 97% improvement of reflux symptoms [18].
Whether a routine preoperative EGD is necessary before
RYGB is controversial. It has been shown that findings
such as peptic ulcer disease, atrophic gastritis, gastric
neoplasms, and other premalignant conditions that make
RYGB contraindicated are quite rare and nearly always
present with a predisposing factor [19]. However, as in our
study, these findings are often asymptomatic [17]. A recent
systematic review concluded that it appears reasonable to
forgo routine preoperative EGD before gastric bypass in the
absence of a clear clinical indication. Yet, they also stated
that concerns remain regarding RYGB and future inacces-
sibility of the excluded stomach [7]. Risk factors for gastric
neoplasms include atrophic gastritis, H. pylori infection,
previous gastric resection, gastric polyps, familial history of
gastric cancer, and smoking [20]. Risk factors for peptic
ulcer disease, include usage of NSAIDs, smoking, age 450
years, H. pylori infection, and chronic kidney, heart, or lung
disease [21]. In our series, we did not find any malignancies
in preoperative EGDs. In our series, only patients who
underwent a bariatric operation were included in the
retrospective analysis; it is possible that some patients were
diagnosed with a malignant finding in EGD before they















































































































Gastroscopy Before Bariatric Surgery / Surgery for Obesity and Related Diseases ] (2018) 00–00 5before RYGB only on patients with a GI symptom or a risk
factor for peptic ulcer disease, atrophic gastritis, or gastric
neoplasm, we would have missed one finding of atrophic
gastritis.
According to a review of esophagogastric cancers after
bariatric procedures in 2013, 28 articles with 33 cases were
published [22]. The review included 8 cancer cases in the
excluded stomach after gastric bypass. Preoperative
endoscopic findings were reported for only 1 case with
gastric intestinal metaplasia before RYGB. The authors
hypothesized that the risk for cancer in the excluded
stomach might be the result of constant exposure of
pancreatobiliary fluids in the excluded stomach and not a
consequence of existing gastric pathology at the time of
bariatric surgery [22].
H. pylori is often encountered in EGD biopsies, but
because H. pylori can also be tested from fecal samples and
with a 13C urease breathing test, we do not think that EGD
is needed for diagnosing H. pylori infection. However, we
must keep in mind that H. pylori is a major carcinogen, and
therefore all patients with a positive H. pylori screening test
should undergo an EGD. Celiac disease can be screened
with serum transglutaminase antibodies and serum pepsin-
ogen I can be used to screen for peptic ulcer disease. Thus,
these diseases do not require EGD for diagnosis.
Our study has several advantages but also some limi-
tations. Our large population comprises all patients that
have undergone a primary bariatric operation during a
nearly 10-year long period and our records cover over
97% of preoperative EGD reports. Our study is limited due
to some heterogeneity in reporting the EGD findings
because preoperative EGD was performed in several endos-
copy units. Also, we did not use a structured symptom
questionnaire.
Conclusions
Based on our study with a large, comprehensive cohort,
we conclude that a preoperative EGD is indicated before
SG, but it is not necessary before RYGB for asymptomatic
patients without any risk factors for gastric pathology
(family history of gastric cancer; H. pylori infection; usage
of NSAIDs; smoking, age 450 yr; chronic kidney, heart, or
lung disease).
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